Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.56 per share a year ago. These ...

On Wednesday, the Colorado Bureau of Investigation (CBI) announced that it will be leading an investigation into a fatal officer-involved shooting that took place north of Durango on Tuesday ...

Speculative activity surged across the micro-cap landscape during the third quarter, fueled by thematic momentum and outsized ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

Datavault AI Inc. ('Datavault AI” or the 'Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial ...

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.